it didn't work for me. I shot them an email last night asking about it.
I like what they do, and looks like they need to do a little more diluting to get the product over the hump and into trials. but, with out any additional information aside from the sec, I'm holding off on jumping in.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.